Up 81.6%: Is Dynavax Technologies Corporation Stock Still a Buy?
Dynavax Technologies Corporation (NASDAQ: DVAX) stock jumped a whopping 81.6% in after-hours trading Friday because of a favorable 12-to-1 advisory committee vote for its experimental hepatitis-B vaccine, Heplisav-B. This panel of independent experts was charged with assessing the vaccine's safety profile for the U.S. Food and Drug Administration, which they deemed sufficient to warrant approval. As the FDA only rarely goes against the advice of its advisory committees, Dynavax appears to be a near lock to gain its first regulatory approval, and finally transition into a commercial-stage company.
Image source: Getty Images.
The outcome of this critical vote was in serious doubt after the FDA released its briefing documents last Wednesday. Specifically, the agency pointed out that patients receiving Heplisav-B exhibited a higher rate of serious adverse effects in its latest phase 3 trial, compared with those receiving GlaxoSmthKline's Engerix-B. Although the data was far from conclusive, this safety concern was enough to cause Dynavax's shares to nosedive by double digits.
Source: Fool.com
Dynavax Technologies Corp Stock
The community is currently still undecided about Dynavax Technologies Corp with 2 Buy predictions and 0 Sell predictions.
Based on the current price of 10.43 € the target price of 26 € shows a potential of 149.28% for Dynavax Technologies Corp which would more than double the current price.
